These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt 2007-001082-15 Etude de Phase I-II multicentrique de l'association Cloretazine-Daunorubicine-Aracytine dans le traitement des leucémies aigües myéloïdes du groupe cytogénétique défavorable. not-yet-due
Not reported 2009-014773-40 Essai de phase II de preuve du concept : Evaluation de l’activité anti-cellules souches cancéreuses du bevacizumab administré en combinaison à la chimiothérapie néoadjuvante dans les cancers du sein 2017-10-06 due-trials
Completed, report not yet due Terminated 2011-000792-14 Etude de phase II évaluant la tolérance et l’efficacité d’un traitement de consolidation par Rituximab sous-cutané à faibles doses chez des patients présentant une leucémie lymphoïde chronique en répo... 2020-07-22 not-yet-due
Exempt 2011-002167-23 A phase Ib/II open-label study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2+/PI3K-activated, trastuzumab-resistant locally advanced, recurrent and metastatic bre... not-yet-due
Exempt 2011-005934-20 Etude de phase I/II d'immunothérapie par protéine recwt1-A10+AS01B après greffe allogénique de cellules souches hématopoïétiques chez des patients porteurs d’une hémopathie myéloïde expri... not-yet-due
Completed, report not yet due 2014-000758-12 Study of pharmacokinetics of intravenous busulfan (Busilvex ®) in the conditioning allogeneic transplantation in patients with high-risk hematological disease. 2020-05-05 not-yet-due
Ongoing 2016-001266-29 Active surveillance with or without a 6 months Apalutamide treatment in low risk prostate cancer: a phase II randomized multicenter trial not-yet-due
Ongoing 2016-001868-11 A prospective, multicentre, open-label, randomized, phase II study of Pembrolizumab in combination with neoadjuvante (F)EC-Paclitaxel regimen in HER2-negative inflammatory breast cancer. not-yet-due
Ongoing 2018-001027-40 ERIBRAIN - A phase II study of Eribulin in brain metastases from HER2-negative breast cancer pre-treated with anthracyclines and taxanes not-yet-due